Ernexa Therapeutics (ERNAW) Non-Current Deferred Tax Liability (2012 - 2017)

Ernexa Therapeutics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $52000.0 in Q4 2017.

• For the quarter ending Q4 2017, Non-Current Deferred Tax Liability rose 6.12% year-over-year to $52000.0; the trailing twelve-month figure through Dec 2017 stood at $52000.0 (up 6.12% YoY), and the FY2017 full-year result was $52000.0, up 6.12% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2017 stood at $52000.0, up from $49000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $900000.0 in Q4 2013, with the low at $49000.0 in Q4 2016.
• Historically, Non-Current Deferred Tax Liability has averaged $333666.7 across 3 years, with a median of $52000.0 in 2017.
• Annual changes were most pronounced in 2013 — Non-Current Deferred Tax Liability soared 1116.22% — and 2017, when it grew 6.12%.
• Ernexa Therapeutics' Non-Current Deferred Tax Liability stood at $900000.0 in 2013, then plunged by 94.56% to $49000.0 in 2016, then rose by 6.12% to $52000.0 in 2017.
• The last three Non-Current Deferred Tax Liability figures came in at $52000.0 (Q4 2017), $49000.0 (Q4 2016), and $900000.0 (Q4 2013), per Business Quant data.